17 detected by IBL total Tau ELISA (AD; 1476 ± 10 vs. NAD; 972 ± 17 pg/mL, ****p < .0001) (Figure 8D) and by IBL p181Tau ELISA (AD; 96 ± 8 vs. NAD; 67 ± 4 pg/mL, **p < .01, unpaired Student's t‐test) (Figure 8E), in spite of statistically lower levels of total brain lysate protein in AD than NAD (***p < .001) (Figure 8C, closed bar), indicating the levels of total Tau and p181Tau detected by IBL kits substantially increased in AD at Fr. This evidence concerns the gene MAPT and Alzheimer disease.